US 5223409A
· Ladner
· 1993
[cited by applicant]
US 7709226B2
· Foote
· 2010
[cited by applicant]
TW 201811828A
· 2018
[cited by applicant]
WO WO2008133722A2
· 2008
[cited by applicant]
WO WO2012149356A2
· 2012
[cited by applicant]
WO WO2014190273A1
· 2014
[cited by applicant]
WO WO2016019300A1
· 2016
[cited by applicant]
WO WO2018023100A2
· 2018
[cited by applicant]
Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins” J Mol Biol, 1997, 273: 927-948.
[cited by applicant]
Alting-Mees et al., “Monoclonal Antibody Expression Libraries: A Rapid Alternative To Hybridomas”, (1990) Strategies in Molecular Biology 3:1-9.
[cited by applicant]
Baines, et al., “Purification of Immunoglobulin G (IgG)”, Methods in Molecular Biology, 1992, vol. 10: Immunochemical Protocols, 10:79-104 (The Humana Press).
[cited by applicant]
Berzofsky, et al. “Antigen-Antibody interaction and Monoclonal Antibodies”, Fundamental immunology, editor, William E. Paul.—7th ed., (2013), Ch 7, Lippincott Williams & Wilkins.
[cited by applicant]
Bird et al., “Single-chain antigen-binding proteins”, 1988, Science 242:423-26.
[cited by applicant]
Bricogne, “[23] Bayesian statistical viewpoint on structure determination: Basic concepts and examples”, Meth Enzymol, 1997, 276A: 361-423.
[cited by applicant]
Bricogne, “Direct phase determination by entropy maximization and likelihood ranking: status report and perspectives”, Acta Crystallogr D Biol Crystallogr, 1993, 49(Pt 1): 37-60.
[cited by applicant]
Bruggenmann et al. “Production of human antibody repertoires in transgenic mice”, 1Curr. Opin. Biotechnol. 1997, 8:455-58.
[cited by applicant]
Burton et al., “Human Antibodies from Combinatorial libraries”, Advances in immunology, 1994, vol. 57, 191-280.
[cited by applicant]
Champe et al., “Monoclonal Antibodies That Block the Activity of Leukocyte Function-associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CD11a”, J Biol Chem, 1995, 270(3): 1388-94.
[cited by applicant]
Chayen, “The role of oil in macromolecular crystallization”, Structure, 1997, 5(10): 1269-1274.
[cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins”, J Mol Biol, 1987, 196: 901-917.
[cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions”, Nature, , 1989, 342(6252):877-883.
[cited by applicant]
Chothia et al., “Structural repertoire of the human VH segments” J Mol Biol, 1992, 227: 799-817.
[cited by applicant]
Cunningham et al., “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis”, Science 244(4908): 1081-85 (1989).
[cited by applicant]
Dayhoff et al. A model of evolutionary change in proteins, in Dayhoff, M.O. Edition, Atlas of Protein Sequence and Structure, 1978, Natl. Biomed. Res. Found., Washington DC, 5(3), 345-352.
[cited by applicant]
De Oliveira et al., “A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors,” Journal of Translational Medicine, Jan. 29, 2013 (Jan. 29, 2013), vol. 11, pp. 1-9.
[cited by applicant]
Evans et al. “Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists” J. Med. Chem, 1987 30:1229-39.
[cited by applicant]
Fauchere, “Elements for the Rational Design of Peptide Drugs”, Advances in Drug Research, vol. 15, 1986, 41 pages.
[cited by applicant]
Gautier et al. “Site-Specific Protein Labeling, Methods and Protocols”, Springer 2015, pp. 1-267.
[cited by applicant]
Giege et al., “Crystallogenesis of biological macromolecules: facts and perspectives”, Acta Crystallogr D Biol Crystallogr, 1994, 50(Pt 4): 339-350.
[cited by applicant]
Golub, et al., “Immunology—A Synthesis (2nd Edition)”, Sinauer Assoc., Sunderland, Mass. (1991), table of contents only, 13 pages.
[cited by applicant]
Hartl et al., “Genetics: Principles and Analysis”, 1997, Jones and Bartlett Publishers.
[cited by applicant]
Heim et al. “Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer”, 1996, Current Biology vol. 6, No. 2:178-182.
[cited by applicant]
Henilkoff et al. “Amino acid substitution matrices from protein blocks”, Proc Natl Acad Sci US A., 89(22): 10915-10919, Nov. 15, 1992.
[cited by applicant]
Holliger et al., “Diabodies: Small Bivalen and Bispecific Antibody Fagments” Proc Natl Acad Sci U.S.A., 1993, 90:6444-48 Biophysics.
[cited by applicant]
Honegger et al. “Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool” J. Mol. Biol., 2001, 309, 657-670.
[cited by applicant]
Hoogenboom et al., “By-passing immunisation”, Journal of Molecular Biology, 1992, 227(2):381-388.
[cited by applicant]
Huse, et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”, Science, 1989, 246(4935):1275-1281.
[cited by applicant]
Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Intl. Search Report—Written Opinion dated Mar. 5, 2018 for PCT/US2017/053790.
[cited by applicant]
Jena, B. et al.; Chimeric Antigen Receptor {CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials; (2013) PLoS One 8(3): e57838. doi:10.1371/journal.pone.0057838.
[cited by applicant]
Johnson et al. “Molecular Probe Handbook A Guide to Fluorescent Probes and Labeling Technologies” 11th Edition, Life Technologies (2010).
[cited by applicant]
Kabat et al. “Sequences of Proteins of Immunological Interest”, 1991, 5th Ed., NIH Publication 91-3242, Bethesda MD title page, publication page, and table of contents only, 10 pages.
[cited by applicant]
Kang et al., “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces”, Proc Natl Acad Sci US A., May 15, 1991, 88(10):4363-6.
[cited by applicant]
Kawalekar, et al. “Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CART Cells,” Immunity, Feb. 16, 2016 (Feb. 16, 2016), vol. 44, pp. 380-390.
[cited by applicant]
Kiebak, et el. “A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer,” Proceedings of the National Academy of Sciences, Jan. 15, 2008 (Jan. 15, 2008), vol. 105, No. 2, pp. 62…
[cited by applicant]
Kochenderfer, J.N., et al.; Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor; J Immunolher. Sep. 2009; pp. 689-702.; 32(7): doi:10.1097/CJI.0b013e3181ac6138.
[cited by applicant]
Korndorfer et al., “Crystallographic Analysis of an “Anticalin” With Tailored Specificity for Fluorescein Reveals High Structural Plasticity of the Lipocalin Loop Region” Proteins: Structure, Function, and Bioinformatic…
[cited by applicant]
Ichiki et al., “Regulation of the expression of human C epsilon germline transcript. Identification of a novel IL-4 responsive element”, http://www.jimmunol.org/content/150/12/5408 J Immunol 1993; 150:5408-5417.
[cited by applicant]
McPherson, “Crystallization of Proteins from Polyethylene Glycol”, J Biol Chem, 1976, 251(20): 6300-6303.
[cited by applicant]
McPherson, “Current approaches to macromolecular crystallization”, Eur J Biochem, 1990, 189: 1-23.
[cited by applicant]
Nicholson et al., Construction and Characterisation of A Functional CD19 Specific Single Chain Fv Fragment for Immunotherapy of B Lineage Leukaemia and Lymphoma Mol Immunol, 1997, vol. 34, No. 16-17:1157-65, Elsavier.
[cited by applicant]
Obermaier et al. “Principles of Protein Labeling Techniques. In: Posch A. (eds) Proteomic Profiling. Methods in Molecular Biology”, 2015, vol. 1295. , Humana Press, New York, NY.
[cited by applicant]
Pan, Y. et al.; Anti-idiotypic Antibodies: Biological Function and Structural Studies; The FASEB Journal, Jan. 1995 p. 43-49; vol. 9, No. 1.
[cited by applicant]
Perisic et al., “Crystal structure of a diabody, a bivalent antibody fragment” Structure, 1994, 2(12): 1217-26.
[cited by applicant]
Poljak et al., “Production and structure of diabodies” Structure, 1994, vol. 2, No. 12: 1121-23.
[cited by applicant]
Roque et al., “Antibodies and Genetically Engineered Related Molecules: Production and Purification”, Biotechnol. Prog. 20:639-654 (2004).
[cited by applicant]
Roversi et al., “Modeling prior distributions of atoms for macromolecular refinement and completion”, Acta Crystallogr D Biol Crystallogr, 2000, 56 (Pt 10): 1316-1323.
[cited by applicant]
Sastry et al. “Cloning of the immunological repertoire in
[cited by applicant]
Schlebusch et al., “Production of a Single-Chain Fragment of the Murine Anti-Idiotypic Antibody ACA125 as Phage-Displayed and Soluble Antibody by Recombinant Phage Antibody Technique”, 1997, Hybridoma 16:47-52.
[cited by applicant]
Stauber et al. “Development and Applications of Enhanced Green Fluorescent Protein Mutants”, BioTechniques, Mar. 1998, vol. 24, No. 3:462-471.
[cited by applicant]
Stocks, “Intrabodies: production and promise” Drug Discovery Today, 2004, 9(22):960-66.
[cited by applicant]
Strack, “Protein labeling in cells”, Nature Methods, Jan. 2016, vol. 13, No. 1, p. 33.
[cited by applicant]
Torikai et al.; “A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR,” Blood, Jun. 14, 2012 (Jun. 14,…
[cited by applicant]
Tramontano et al., “Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins” J Mol Biol, 1990, 215(1): 175-82.
[cited by applicant]
Verber, et al., “The design of metabolically-stable peptide analogs,”. Trends in Neurosciences, Sep. 1985, pp. 392-396.
[cited by applicant]
Winter, et al., “Making Antibodies by Phage Display Technology”, Annual Review of Immunology, Publication Annual Review of Immunology, 1994, 12(1):433-455.
[cited by applicant]
Wyckoff et al., eds., Methods in Enzymology vol. 114—Diffraction Methods for Biological Macromolecules, Academic Press, Orlando, FL; title page, publication page, and table of contents only, 5 pages (1985).
[cited by applicant]
Wyckoff et al., eds., Methods in Enzymology vol. 115. Diffraction Methods for Biological Macromolecules, Academic Press, Orlando, FL; title page, publication page, and table of contents only, 4 pages (1985).
[cited by applicant]
Zheng, el al., “Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry,” Journal of Translational Medicine, Feb. 13, 2012(Feb. 13, 2012), vol. 10, pp. 1-6.
[cited by applicant]
Zola, Y. et al.; Preparation and Characterization of a Chimeric CD19 Monoclonal Antibody:Immunology and Cell Biology; Dec. 1991; pp. 411-422; 69 { PI 6).
[cited by applicant]
Wu et al., “From Therapeutic Antibodies to Chimeric Antigen Receptors (CARs): Making Better CARs Based on Antigen-Binding Domain,” Expert Opinion on Biological Therapy, vol. 16, No. 12, (2016), pp. 1469-1478.
[cited by applicant]
Park et al., “CD19-Targeted CAR T-Cell Therapeutics for Hematologic Malignancies: Interpreting Clinical Outcomes to Date,” Blood, vol. 127, No. 26, (2016), pp. 3312-3320.
[cited by applicant]
Kochenderfer et al., “B-Cell Depletion and Remissions of Malignancy along with Cytokine-Associated Toxicity in a Clinical Trial of Anti-CD19 Chimeric-Antigen-Receptor-Transduced T Cells,” Bood, vol. 119, No. 12, (2011),…
[cited by applicant]
Extended European Search Report, issued in EP Application No. 17857353, dated Jun. 18, 2020.
[cited by applicant]
Office Action dated Jul. 27, 2020 in Taiwanese Appl. No. 109114726.
[cited by applicant]
Office Action dated Feb. 27, 2019 in Taiwanese Appl. No. 106133121.
[cited by applicant]
Non-Final Office Action dated Aug. 7, 2019 in U.S. Appl. No. 15/717,691.
[cited by applicant]
Notice of Allowance dated Dec. 11, 2019 in U.S. Appl. No. 15/717,691.
[cited by applicant]
Decision of Rejection dated Jul. 17, 2019 in Taiwanese Appl. No. 106133121.
[cited by applicant]
Baines, et al., “Purification ofImmunoglobu1in G (IgG)”, Methods in Molecular Biology, 1992, vol. 10: Immunochemical Protocols, 10:79-104 (The Humana Press).
[cited by applicant]
Communication pursuant to Article 94(3) EPC dated May 12, 2021 for European Appl. No. 17857353.1.
[cited by applicant]
Office Action dated Dec. 12, 2022 for European Appl. No. 17857353.1.
[cited by applicant]